Horn DL, Fishman JA, Steinbach WJ, et al: Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007; 59:407-414. (Pubitemid 350186332)
Wisplinghoff H, Bischoff T, Tallent SM, et al: Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study [Erratum appears in Clin Infect Dis 2004; 39:1093] [Erratum appears in Clin Infect Dis 2005; 40:1077]. Clin Infect Dis 2004; 39: 309-317.
Garbino J, Kolarova L, Rohner P, et al: Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) 2002; 81:425-433. (Pubitemid 35285962)
Leleu G, Aegerter P, Guidet B, et al: Systemic candidiasis in intensive care units: A multicenter, matched-cohort study. J Crit Care 2002; 17:168-175.
Choi HK, Jeong SJ, Lee HS, et al: Blood stream infections by Candida glabrata and Candida krusei: A single-center experience. Korean J Intern Med 2009; 24:263-269.
Marriott DJE, Playford EG, Chen S, et al: Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care 2009; 13:R115.
Moran C, Grussemeyer CA, Spalding JR, et al: Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. Am J Infect Control 2010; 38:78-80.
Rentz AM, Halpern MT, Bowden R: The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27:781-788. (Pubitemid 29244335)
Pelz RK, Lipsett PA, Swoboda SM, et al: Candida infections: Outcome and attributable ICU costs in critically ill patients. J Intensive Care Med 2000; 15:255-261.
Wilson LS, Reyes CM, Stolpman M, et al: The direct cost and incidence of systemic fungal infections. Value Health 2002; 5:26-34. (Pubitemid 34160368)
Gudlaugsson O, Gillespie S, Lee K, et al: Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-1177. (Pubitemid 37372504)
Zaoutis TE, Argon J, Chu J, et al: The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis 2005; 41:1232-1239. (Pubitemid 41532664)
Falagas ME, Apostolou KE, Pappas VD: Attributable mortality of candidemia: A systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006; 25:419-425. (Pubitemid 44078593)
Hassan I, Powell G, Sidhu M, et al: Excess mortality, length of stay and cost attributable to candidaemia. J Infect 2009; 59:360-365.
Charlier C, Hart E, Lefort A, et al: Fluconazole for the management of invasive candidiasis: Where do we stand after 15 years? J Antimicrob Chemother 2006; 57:384-410. (Pubitemid 43240191)
Garey KW, Rege M, Pai MP, et al: Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 2006; 43:25-31. (Pubitemid 43939072)
Pappas PG, Kauffman CA, Andes D, et al: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-535.
Mora-Duarte J, Betts R, Rotstein C, et al: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-2029. (Pubitemid 35461658)
Kuse E-R, Chetchotisakd P, da Cunha CA, et al: Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet 2007; 369:1519-1527. (Pubitemid 46670281)
Pappas PG, Rotstein CMF, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis [Erratum appears in Clin Infect Dis 2008; 47:302]. Clin Infect Dis 2007; 45: 883-893. (Pubitemid 47580382)
Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-2482. (Pubitemid 46919773)
Almirante B, Rodriguez D, Park BJ, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43:1829-1835.
Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance [Erratum appears in J Clin Microbiol 2008; 46: 3184 -3185]. J Clin Microbiol 2008; 46: 150-156.
Pfaller MA, Messer SA, Hollis RJ, et al. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007. J Clin Microbiol 2009; 47:3185-3190.
Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37:634-643. (Pubitemid 37100802)
Vincent J-L, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-2329.
Le Gall JR, Lemeshow S, Saulnier F: A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study [Erratum appears in JAMA 1994; 271:1321]. JAMA 1993; 270:2957-2963. (Pubitemid 24000804)
Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/ failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22:707-710. (Pubitemid 26254283)
Calandra T, Cohen J; International Sepsis Forum Definition of Infection in the ICUCC. The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit. Crit Care Med 2005; 33:1538-1548. (Pubitemid 40980610)
Rangel-Frausto MS, Wiblin T, Blumberg HM, et al. National Epidemiology of Mycoses Survey (NEMIS): Variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999; 29:253-258. (Pubitemid 29380179)
Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26:271-276. (Pubitemid 46572022)
Garrouste-Orgeas M, Timsit JF, Tafflet M, et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: A reappraisal [Erratum appears in Clin Infect Dis 2006; 42:1818]. Clin Infect Dis 2006; 42:1118-1126.
Vincent JL, Anaissie E, Bruining H, et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998; 24:206-216. (Pubitemid 28190811)
Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia. A matched case- control study. Arch Intern Med 1989; 149:2349-2353. (Pubitemid 19258182)
Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34:730-737.
Schuster MG, Edwards JE Jr, Sobel JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: A randomized trial. Ann Intern Med 2008; 149:83-90. (Pubitemid 352008596)
Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-3645. (Pubitemid 41233011)
Parkins MD, Sabuda DM, Elsayed S, et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60:613-618. (Pubitemid 47299877)
Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidaemia in Europe: Results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23:317-322. (Pubitemid 38669942)
Magill SS, Swoboda SM, Johnson EA, et al. The association between anatomic site of Candida colonization, invasive candidiasis, and mortality in critically ill surgical patients [Erratum appears in Diagn Microbiol Infect Dis 2007; 57:351]. Diagn Microbiol Infect Dis 2006; 55:293-301. (Pubitemid 44137494)
Meersseman W, Lagrou K, Spriet I, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: A prospective, autopsy study. Intensive Care Med 2009; 35:1526-1531.
Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000; 30:14-18. (Pubitemid 30067055)
Tambyah PA, Maki DG: Catheter-associated urinary tract infection is rarely symptomatic: A prospective study of 1,497 catheterized patients. Arch Intern Med 2000; 160: 678-682. (Pubitemid 30140418)
Sandven P, Giercksky KE, Group N, et al. Yeast colonization in surgical patients with intra-abdominal perforations. Eur J Clin Microbiol Infect Dis 2001; 20:475-481 (Pubitemid 34212108)
